Genmab ASMEX:GMABN 92 Gross Margin % is 92.75% as of Mar. 2026, which is 3% below its 10-year median of 95.42. GuruFocus rates MEX:GMABN with a GF Score™ of 92/100 and a GF Value™ of MXN5,328.99 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 737 Biotechnology companies, Genmab AS ranks better than 90.23% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Genmab AS's Gross Profit for the
three
months ended in Mar. 2026 was MXN14,985 Mil. Genmab AS's Revenue for the
three
months ended in Mar. 2026 was MXN16,157 Mil. Therefore, Genmab AS's Gross Margin % for the quarter that ended in Mar. 2026 was 92.75%.
The historical rank and industry rank for Genmab AS's Gross Margin % or its related term are showing as below:
MEX:GMABN'
s Gross Margin % Range Over the Past 10 Years
Min: 93.31 Med: 95.42 Max: 98.62
Current: 93.31
During the past 13 years, the highestGross Margin % of Genmab AS was 98.62%. The lowest was 93.31%. And the median was 95.42%.
MEX:GMABN's Gross Margin % is ranked better than 90.23% of 737
companies
in the Biotechnology industry
Industry Median: 60.92
vs MEX:GMABN: 93.31
Genmab AS had a gross margin of 92.75% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Genmab AS was 0.00% per year.
Genmab AS (MEX:GMABN) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Genmab AS had a gross margin of 92.75% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Genmab AS Gross Margin % Related Terms
Genmab AS Gross Margin % Historical Data
* Premium members only.
The historical data trend for Genmab AS's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:GMABN vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Genmab AS's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genmab AS Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genmab AS's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Genmab AS's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Genmab AS (MEX:GMABN) has a Gross Margin % of 92.75% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Genmab AS and its competitors. This is near median its historical median of 95.42. Over the past decade, Genmab AS's Gross Margin % has ranged from 93.31 to 98.62. According to the industry distribution chart, Genmab AS ranks #72 out of 737 companies in the Biotechnology industry, placing it in the top 9.8%.
Is Genmab AS's Gross Margin % too high?
Genmab AS's current Gross Margin % of 92.75% is near median its 10-year median of 95.42. Over the past 10 years, this metric has ranged from a low of 93.31 to a high of 98.62. The Biotechnology industry median Gross Margin % is 60.92. Genmab AS's value of 92.75% is 52.2% above this industry median. Based on the distribution chart, Genmab AS ranks #72 out of 737 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Genmab AS has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genmab AS ranks #72 out of 737 companies for Gross Margin %. This places Genmab AS in the top 10% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.92. Genmab AS's value of 92.75% is 52.2% above this benchmark. Historically, Genmab AS's own Gross Margin % has ranged from 93.31 to 98.62 over the past decade. While the company's 10-year median is 95.42 vs. the industry median of 60.92, Genmab AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genmab AS's current Gross Margin % of 92.75% is 52.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Genmab AS and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genmab AS's current Gross Margin % is 92.75%, which is near median its own 10-year median of 95.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (MEX:GMABN) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN5,328.99, compared to a current price of MXN4,027.79 — trading 24.4% below its estimated fair value. The current Gross Margin % is 92.75%, which is near median its 10-year median of 95.42 and 52.2% above the Biotechnology industry median of 60.92. Genmab AS's overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Genmab AS (MEX:GMABN), the current Gross Margin % is 92.75% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genmab AS (MEX:GMABN) Overvalued in 2026?
Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued.
The current stock price of MXN4,027.79 is trading 24.4% below its estimated GF Value™ of MXN5,328.99.
GuruFocus considers Genmab AS to be Modestly Undervalued.
Key valuation signals for MEX:GMABN:
Gross Margin %: 92.75% (near median its 10-year median of 95.42)
GF Value™: MXN5,328.99 vs. price of MXN4,027.79 (24.4% below fair value)
Industry Position: 52.2% above the Biotechnology median (#72 of 737)
No single metric tells the full story. See the MEX:GMABN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
92GF Score
Get the complete analysis for MEX:GMABN
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:GMABN has been successfully added to your 
